Pharmaceutical Giants Join Forces to Enhance AI Drug Discovery Capabilities

Bristol-Myers Squibb, Takeda, and Astex are collaborating with an existing consortium to train the AI model OpenFold3 for drug discovery. The companies will contribute data from thousands of protein-small molecule structures to improve OpenFold3's accuracy in predicting interactions, a crucial step in drug discovery and development. The initiative uses a federated data sharing model provided by Apheris to securely aggregate diverse datasets.